-
L124802-5gLevocetirizine dihydrochloride.
-
L129269-100gLevodropropizine.
-
L129269-1gLevodropropizine.
-
L129269-25gLevodropropizine.
-
L129269-5gLevodropropizine.
-
L647857-10mgLFHP-1c is an PGAM5 inhibitor with neuroprotective activity in brain ischemic stroke. LFHP-1c protects blood-brain barrier integrity from ischemia-induced injury. LFHP-1c binds to endothelial PGAM5 to inhibit the activity of PGAM5 phosphatase and
-
L647857-25mgLFHP-1c is an PGAM5 inhibitor with neuroprotective activity in brain ischemic stroke. LFHP-1c protects blood-brain barrier integrity from ischemia-induced injury. LFHP-1c binds to endothelial PGAM5 to inhibit the activity of PGAM5 phosphatase and
-
L647857-5mgLFHP-1c is an PGAM5 inhibitor with neuroprotective activity in brain ischemic stroke. LFHP-1c protects blood-brain barrier integrity from ischemia-induced injury. LFHP-1c binds to endothelial PGAM5 to inhibit the activity of PGAM5 phosphatase and
-
L647702-10mgLHVS is a potent, non-selective, irreversible, cell-permeable cysteine protease and cathepsin inhibitor. LHVS decreases actin ring formation. LHVS inhibits T. gondii invasion with an IC 50 of 10 μMIn VitroLHVS (5 μM, 2 h) results in a 50% reduction
-
L647702-5mgLHVS is a potent, non-selective, irreversible, cell-permeable cysteine protease and cathepsin inhibitor. LHVS decreases actin ring formation. LHVS inhibits T. gondii invasion with an IC 50 of 10 μMIn VitroLHVS (5 μM, 2 h) results in a 50% reduction
-
L655138-1mlLHVS is a potent, non-selective, irreversible, cell-permeable cysteine protease and cathepsin inhibitor. LHVS decreases actin ring formation. LHVS inhibits T. gondii invasion with an IC 50 of 10 μMIn VitroLHVS (5 μM, 2 h) results in a 50% reduction
-
L651454-10mgLicarin B, a nitric oxide production inhibitor extracted from the component of the seeds of Myristica fragrans , improves insulin sensitivity via PPARγ and activation of GLUT4 in the IRS-1/PI3K/AKT pathwayIn VitroLicarin B (5 μM, 10 μM, 15 μM. 8